Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

See Her Screen Her: An opportunistic VIA screening and HPV vaccination among female patient attendants at a tertiary cancer care center in a low-resource setting.

Jannatul Ferdause Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22518

e22518 Background: Cervical cancer remains one of the major causes of cancer mortality in low- and middle-income countries...

Impact of baseline severe cytopenia on post–BCMA CAR T-cell therapy outcomes in multiple myeloma: A propensity-matched multicenter study.

Jesus Alberto Gomez, Divya Samat, Manas Pustake et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19527

e19527 Background: Severe cytopenias are common in relapsed/refractory multiple myeloma (MM) and may influence outcomes af...

Efficacy and safety of durvalumab with or without tremelimumab in metastatic NSCLC: A meta-analysis of randomized controlled trials.

Ursula Medeiros Araujo de Matos, Henrique Guimaraes Barbosa Coelho, Moana Divina Da Silva Santiago et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20568

e20568 Background: Lung cancer remains the leading cause of cancer-related mortality worldwide. Non–small cell lung cancer...

An immune-related pathologic response score as a predictor of survival after immune checkpoint inhibitor–based conversion therapy in hepatocellular carcinoma.

Yi-Jun Lu, Rui-Zhe Li, Wen-Jing Zheng et al. Jun 01, 2026 pp. 4162-4162 10.1200/jco.2026.44.16_suppl.4162

4162 Background: Immune checkpoint inhibitor (ICI) based conversion therapy is increasingly utilized in the management of...

Association of caregiver and patient burden with ALK-positive advanced non–small cell lung cancer in Germany, the United Kingdom, and the United States.

Hoa Le, Hollie Bailey, Helen Burlison et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20768

e20768 Background: Patients with advanced NSCLC (aNSCLC) can experience significant disease burden with respect to symptom...

A phase II study of ubenimex combined with pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non–small cell lung cancer: TORG2241(UBE-Q).

Akane Narumi, Shinji Nakamichi, Kaoru Kubota et al. Jun 01, 2026 pp. 8559-8559 10.1200/jco.2026.44.16_suppl.8559

8559 Background: Pembrolizumab plus platinum-based chemotherapy is a standard first-line treatment for previously untreate...

Palliative care utilization in patients with <i>EGFR</i> -mutant metastatic non-small cell lung cancer receiving first-line <i>EGFR</i> TKIs.

Divya Chukkalore, Wint Yan Aung, Nina Cheranda et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24076

e24076 Background: Patients with metastatic EGFR -mutant NSCLC experience prolonge...

Effect of "watch and wait" on fear of recurrence in rectal cancer: A multicenter cross-sectional study.

Ahmet Oruç, Galip Can Uyar, Latif Karahan et al. Jun 01, 2026 pp. 12116-12116 10.1200/jco.2026.44.16_suppl.12116

12116 Background: Total neoadjuvant therapy (TNT) is now the standard of care for locally advanced rectal cancer. Watch-an...

H&amp;E 2.0: Artificial intelligence–driven prediction of N256-glycosylated CEACAM5/6 expression in esophageal and gastric adenocarcinomas.

Felicia Wee, Zhen Wei Neo, Rachel Elizabeth Ann Fincham et al. Jun 01, 2026 pp. 4018-4018 10.1200/jco.2026.44.16_suppl.4018

4018 Background: The antibody-drug conjugate (ADC) EBC-129 has shown promising clinical responses in a Phase 1A/B trial, w...

NCORP Symptom Science Portfolio analysis (2014-2025).

Cecilia Lee, Rachel Altshuler, Brennan Streck et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24054

e24054 Background: Symptom science research constitutes the largest share of the Division of Cancer Prevention’s portfolio...

Barriers and facilitators to teleoncology care delivery for cognitively impaired older cancer patients: Clinician perspectives.

Amber Soublet, Jeanette Torres Ybarra, Michael Steinman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13710

e13710 Background: Telehealth has improved access to care and is increasingly used in oncology. However, its expansion has...

Respiratory malignancies among patients hospitalized with acute respiratory failure: Nationwide trends in complications, resource utilization, and outcomes.

Amit Krishnan, Heng Jiang, Harsha Pattnaik et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20085

e20085 Background: Acute respiratory failure (ARF) is a common cause of hospitalization among patients with lung cancer. P...

Variation in metastatic colorectal cancer (mCRC) patient survival among different oncology practice settings with guideline-concordant molecular testing.

Tony Varughese, Wenners Ballard, Chiranjeev Dash et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23082

e23082 Background: Molecular testing is paramount for treating patients (pts) with mCRC. Guidelines, including ASCO and NC...

Prognostic impact of comorbidity burden on overall survival in patients with Waldenström macroglobulinemia in the United States.

Gaelle Haddad, Hong Liang, Chieh Lin Fu et al. Jun 01, 2026 pp. 7083-7083 10.1200/jco.2026.44.16_suppl.7083

7083 Background: Waldenström macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma (LPL), is a rare indolent No...

Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).

Andrew J. Wagner, Jonathan C. Trent, William D. Tap et al. Jun 01, 2026 pp. 11500-11500 10.1200/jco.2026.44.16_suppl.11500

11500 Background: GIST, the most common mesenchymal malignancy of the gastrointestinal tract, is commonly driven b...

Tumor methylation subtypes as a predictor of clinical outcome to immunotherapy in pleural mesothelioma patients from the NIBIT-EPI-MESO study.

Luana Calabrò, Francesca Pia Caruso, Alessia Covre et al. Jun 01, 2026 pp. 8052-8052 10.1200/jco.2026.44.16_suppl.8052

8052 Background: Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis. The clinicalefficacy of stan...

Clinical characteristics, treatment patterns, and outcomes of patients aged ≥ 80 years with aggressive lymphomas: A real-world single-center experience.

Juliana Castro, Manuela Estrada, Laura Ortiz et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13772

e13772 Background: Population aging has led to a growing number of patients aged ≥80 years diagnosed with lymphoma. Howeve...

Outcomes of immune checkpoint inhibitor therapy in patients with pre-existing autoimmune disease: A propensity-matched real-world analysis of baseline corticosteroid use.

Layal Sharrouf, Waqqas Tai, Momna Nisar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23096

e23096 Background: Patients with pre-existing autoimmune disease are frequently excluded from immune checkpoint inhibitor...

Budget impact analysis of heated intraperitoneal chemotherapy at interval cytoreductive surgery for stage III high grade serous carcinoma of tubo-ovarian origin.

Tal Milman, Charlotte Clayton, Lien Hoang et al. Jun 01, 2026 pp. 5589-5589 10.1200/jco.2026.44.16_suppl.5589

5589 Background: Heated Intraperitoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (ICS) for high grade serous...

Association of GLP-1 receptor agonist use with overall survival in patients with colorectal cancer and type 2 diabetes: A multicenter real-world study.

Baqir Jafry, Anahat Kaur, Jennifer Collins et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15556

e15556 Background: Colorectal cancer (CRC) is closely linked to obesity and type 2 diabetes mellitus (T2DM), conditions as...

Pilot study of CTC enumeration and AR-V7 detection using a microporous chip filtration system in metastatic prostate cancer.

Hyun Suk Yoon, Jihyun Lee, Minseon Hwang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17054

e17054 Background: Circulating tumor cells (CTC) are one of key components of liquid biopsy which provide phenotype and mo...

Effects of SECN-15, a neuropilin-1–targeting antisense oligonucleotide, on resistance to immune checkpoint inhibitors in preclinical tumor models.

Richard Klar, Anne Sadewasser, Julia Festag et al. Jun 01, 2026 pp. 2613-2613 10.1200/jco.2026.44.16_suppl.2613

2613 Background: Neuropilin-1 (NRP1) is a transmembrane co-receptor implicated in tumor growth, metastasis, angiogenesis,...

Comparative assessment of skin toxicity in prone vs supine positions during preoperative breast radiotherapy: A systematic review and meta-analysis.

Aizaz Anwar Khalid, Muhammad Yasir, Hassaan Qazi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24148

e24148 Background: Skin toxicity remains one of the most common side effects of breast radiotherapy and can meaningfully a...

First-line carboplatin-paclitaxel (CP) for metastatic anal squamous cell carcinoma (ASCC): An analysis of dosing schedules.

Jakob Skyler Hamilton, Oluwatayo Adeoye, Umair Majeed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15501

e15501 Background: CP is the backbone of first-line therapy for recurrent or metastatic ASCC. In practice, Q3-week CP has...

Real-world cardiotoxicity with HER2 antibody–drug conjugates and survival after treatment continuation.

Sumbal Aziz, Woo Joo Lee, Mustafa Ali Samejo et al. Jun 01, 2026 pp. 1057-1057 10.1200/jco.2026.44.16_suppl.1057

1057 Background: HER2 antibody–drug conjugates (ADCs) are central to HER2-positive breast cancer (BC) treatment, yet cardi...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page